User menu

Expression profile of the human IDO1 protein, a cancer drug target involved in tumoral immune resistance

Bibliographic reference Vigneron, Nathalie ; van Baren, Nicolas ; Van den Eynde, Benoît. Expression profile of the human IDO1 protein, a cancer drug target involved in tumoral immune resistance. In: OncoImmunology, Vol. 4, no. 5, p. e1003012 (2015)
Permanent URL
  1. Theate I., van Baren N., Pilotte L., Moulin P., Larrieu P., Renauld J.-C., Herve C., Gutierrez-Roelens I., Marbaix E., Sempoux C., Van den Eynde B. J., Extensive Profiling of the Expression of the Indoleamine 2,3-Dioxygenase 1 Protein in Normal and Tumoral Human Tissues, 10.1158/2326-6066.cir-14-0137
  2. Smith Courtney, Chang Mee Young, Parker Katherine H., Beury Daniel W., DuHadaway James B., Flick Hollie E., Boulden Janette, Sutanto-Ward Erika, Soler Alejandro Peralta, Laury-Kleintop Lisa D., Mandik-Nayak Laura, Metz Richard, Ostrand-Rosenberg Suzanne, Prendergast George C., Muller Alexander J., IDO Is a Nodal Pathogenic Driver of Lung Cancer and Metastasis Development, 10.1158/
  3. Wang Yutang, Liu Hanzhong, McKenzie Gavin, Witting Paul K, Stasch Johannes-Peter, Hahn Michael, Changsirivathanathamrong Dechaboon, Wu Ben J, Ball Helen J, Thomas Shane R, Kapoor Vimal, Celermajer David S, Mellor Andrew L, Keaney John F, Hunt Nicholas H, Stocker Roland, Kynurenine is an endothelium-derived relaxing factor produced during inflammation, 10.1038/nm.2092
  4. Lee Jeffrey R, Dalton Rory R, Messina Jane L, Sharma Madhav D, Smith David M, Burgess Russell E, Mazzella Fermina, Antonia Scott J, Mellor Andrew L, Munn David H, Pattern of Recruitment of Immunoregulatory Antigen-Presenting Cells in Malignant Melanoma, 10.1097/01.lab.0000090158.68852.d1
  5. Spranger Stefani, Koblish Holly K, Horton Brendan, Scherle Peggy A, Newton Robert, Gajewski Thomas F, Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8+ T cells directly within the tumor microenvironment, 10.1186/2051-1426-2-3
  6. Taube J. M., Anders R. A., Young G. D., Xu H., Sharma R., McMiller T. L., Chen S., Klein A. P., Pardoll D. M., Topalian S. L., Chen L., Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape, 10.1126/scitranslmed.3003689
  7. Tumeh Paul C., Harview Christina L., Yearley Jennifer H., Shintaku I. Peter, Taylor Emma J. M., Robert Lidia, Chmielowski Bartosz, Spasic Marko, Henry Gina, Ciobanu Voicu, West Alisha N., Carmona Manuel, Kivork Christine, Seja Elizabeth, Cherry Grace, Gutierrez Antonio J., Grogan Tristan R., Mateus Christine, Tomasic Gorana, Glaspy John A., Emerson Ryan O., Robins Harlan, Pierce Robert H., Elashoff David A., Robert Caroline, Ribas Antoni, PD-1 blockade induces responses by inhibiting adaptive immune resistance, 10.1038/nature13954
  8. Spranger S., Spaapen R. M., Zha Y., Williams J., Meng Y., Ha T. T., Gajewski T. F., Up-Regulation of PD-L1, IDO, and Tregs in the Melanoma Tumor Microenvironment Is Driven by CD8+ T Cells, 10.1126/scitranslmed.3006504
  9. Uyttenhove Catherine, Pilotte Luc, Théate Ivan, Stroobant Vincent, Colau Didier, Parmentier Nicolas, Boon Thierry, Van den Eynde Benoît J, Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase, 10.1038/nm934
  10. Riesenberg R., Weiler C., Spring O., Eder M., Buchner A., Popp T., Castro M., Kammerer R., Takikawa O., Hatz R. A., Stief C. G., Hofstetter A., Zimmermann W., Expression of Indoleamine 2,3-Dioxygenase in Tumor Endothelial Cells Correlates with Long-term Survival of Patients with Renal Cell Carcinoma, 10.1158/1078-0432.ccr-07-0942